|
Statement
| 1.Date of the board of directors resolution:2022/03/01
2.Name [issue no.__ of (secured, unsecured) corporate
bonds of ___________ (company)]:
issue 1st of unsecured convertible corporate
bonds of Medigen vaccine biologics corporation.
3.Whether to adopt shelf registration(Yes/No):No.
4.Total amount issued: equals to the ceiling NT$1,750,000,000
5.Face value per bond:NT$100,000
6.Issue price::Issued at 100% ~ 100.5% of the face value
7.Issuance period:3 years
8.Coupon rate:The coupon rate is 0% per annum
9.Types, names, monetary values and stipulations of collaterals:none.
10.Use of the funds raised by the offering and utilization plan:
Enrichment of working capital
11.Underwriting method:Public underwriting will be carried out by way of
enquiry and book building
12.Trustees of the corporate bonds:Authorize the chairman's decision.
13.Underwriter or agent:Authorize the chairman's decision.
14.Guarantor(s) for the issuance:Authorize the chairman's decision.
15.Agent for payment of the principal and interest:
Authorize the chairman's decision.
16.Certifying institution:N/A
17.Where convertible into shares, the price and the rules for conversion:
Relevant measures will be handled in accordance with relevant laws and
regulations and reported to government authority.
a further announcement will be made after approval.
18.Sell-back conditions:
Relevant measures will be handled in accordance with relevant laws
and regulations, and will be announced separately after being reported
to government authority for approval.
19.Buyback conditions:
Relevant measures will be handled in accordance with relevant laws
and regulations, and will be announced separately after being reported
to government authority for approval.
20.Reference date for any additional share exchange,
stock swap, or subscription:
Relevant measures will be handled in accordance with relevant laws
and regulations, and will be announced separately after being reported
to government authority for approval.
21.Possible dilution of equity in case of any additional
share exchange, stock swap, or subscription:
Relevant measures will be handled in accordance with relevant laws
and regulations, and will be announced separately after being reported
to government authority for approval.
22.Any other matters that need to be specified:
The issue amount,conditions and issue of first domestic unsecured
convertible corporate bonds, and revision of conversion method, and
total amount of funds required for this plan, the source of funds,
the planned projects, the progress of funds,expected benefits and
other issues related to issuance. When it's necessary to make or
amend due to objective circumstances, the Company authorizes the
chairman of the board to deal with it.
|
